Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


04.03.2019

1 Eur J Gastroenterol Hepatol
1 Gastroenterology
1 Hepatology
1 J Gastroenterol
2 J Hepatol
6 J Viral Hepat
3 PLoS One
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Eur J Gastroenterol Hepatol

  1. SANDMANN L, Dorge P, Wranke A, Vermehren J, et al
    Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
    Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386.
    PubMed     Text format     Abstract available


    Gastroenterology

  2. TORRES HA, Pundhir P, Mallet V
    Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis.
    Gastroenterology. 2019 Feb 21. pii: S0016-5085(19)30435.
    PubMed     Text format    


    Hepatology

  3. YANG JD, Gores GJ
    Does Cirrhosis Associated with Well Controlled Viral Hepatitis Confer a Risk for Extrahepatic Cancer?
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063.
    PubMed     Text format    


    J Gastroenterol

  4. UEDA Y, Kobayashi T, Ikegami T, Miuma S, et al
    Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    J Gastroenterol. 2019 Feb 26. pii: 10.1007/s00535-019-01561.
    PubMed     Text format     Abstract available


    J Hepatol

  5. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30128.
    PubMed     Text format     Abstract available

  6. MORGAN FREIMAN J, Wang J, Easterbrook PJ, Robert Horsburgh C, et al
    Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30125.
    PubMed     Text format     Abstract available


    J Viral Hepat

  7. VANOPDORP JR, Ferrentino N, Strader DB, Lidofsky SD, et al
    Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct acting antiviral regimens.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13083.
    PubMed     Text format     Abstract available

  8. LATHAM NH, Pedrana A, Doyle JS, Howell J, et al
    Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13087.
    PubMed     Text format     Abstract available

  9. DORE GJ
    HCV reinfection as a positive indication of high-risk population treatment access.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13092.
    PubMed     Text format     Abstract available

  10. TURKOVA A, Volynets GV, Crichton S, Skvortsova TA, et al
    Advanced liver disease in Russian children and adolescents with chronic hepatitis C.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13093.
    PubMed     Text format     Abstract available

  11. PLATT L, Stengel CM, Nkurunziza M, Muhangi D, et al
    Assessing risk of HIV and hepatitis C among people who inject drugs in East Africa: findings from a rapid assessment.
    J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13088.
    PubMed     Text format     Abstract available

  12. WILSON EC, Turner C, Lin J, McFarland W, et al
    Hepatitis C seroprevalence and engagement in related care and treatment among transwomen.
    J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13089.
    PubMed     Text format     Abstract available


    PLoS One

  13. VILLAR LM, Geloneze B, Vasques ACJ, Pires MLE, et al
    Prevalence of hepatitis B and hepatitis C among diabetes mellitus type 2 individuals.
    PLoS One. 2019;14:e0211193.
    PubMed     Text format     Abstract available

  14. GRANADOS-GARCIA V, Flores YN, Diaz-Trejo LI, Mendez-Sanchez L, et al
    Estimating the prevalence of hepatitis C among intravenous drug users in upper middle income countries: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0212558.
    PubMed     Text format     Abstract available

  15. OWUSU M, Bonney JK, Annan AA, Mawuli G, et al
    Aetiology of viral hepatitis among jaundiced patients presenting to a tertiary hospital in Ghana.
    PLoS One. 2018;13:e0203699.
    PubMed     Text format     Abstract available


    Virology

  16. JALAL PJ, King BJ, Saeed A, Adedeji Y, et al
    Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection.
    Virology. 2019;530:99-106.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: